Investigational Drug Information for DEBIO-1347
✉ Email this page to a colleague
What is the drug development status for DEBIO-1347?
DEBIO-1347 is an investigational drug.
There have been 24 clinical trials for DEBIO-1347.
The most recent clinical trial was a Phase 2 trial, which was initiated on August 7th 2020.
The most common disease conditions in clinical trials are Bacterial Infections, Lymphoma, and Hepatitis, Chronic. The leading clinical trial sponsors are Debiopharm International SA, Merck Sharp & Dohme Corp., and Centre Leon Berard.
There are five US patents protecting this investigational drug and eighty-two international patents.
Summary for DEBIO-1347
| US Patents | 5 |
| International Patents | 82 |
| US Patent Applications | 14 |
| WIPO Patent Applications | 8 |
| Japanese Patent Applications | 7 |
| Clinical Trial Progress | Phase 2 (2020-08-07) |
| Vendors | 47 |
Recent Clinical Trials for DEBIO-1347
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) | Debiopharm International SA | Phase 1 |
| A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors | Debiopharm International SA | Phase 1 |
| A Study of Debio 1143 (Xevinapant) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitiv | GORTEC (Head and Neck Oncology and Radiotherapy Group) | Phase 3 |
Clinical Trial Summary for DEBIO-1347
Top disease conditions for DEBIO-1347
Top clinical trial sponsors for DEBIO-1347
US Patents for DEBIO-1347
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| DEBIO-1347 | See Plans and Pricing | FGFR gatekeeper mutant gene and drug targeting same | Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP) | See Plans and Pricing |
| DEBIO-1347 | See Plans and Pricing | FGFR3 fusion gene and pharmaceutical drug targeting same | Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP) | See Plans and Pricing |
| DEBIO-1347 | See Plans and Pricing | Aminopyrazole derivative | Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP) F. Hoffmann-La Roche AG (Basel, CH) | See Plans and Pricing |
| DEBIO-1347 | See Plans and Pricing | Aminopyrazole derivative | Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP) F. Hoffmann-La Roche AG (Basel, CH) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for DEBIO-1347
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| DEBIO-1347 | Denmark | DK3087986 | 2033-12-27 | See Plans and Pricing |
| DEBIO-1347 | European Patent Office | EP3087986 | 2033-12-27 | See Plans and Pricing |
| DEBIO-1347 | European Patent Office | EP3581179 | 2033-12-27 | See Plans and Pricing |
| DEBIO-1347 | Spain | ES2756175 | 2033-12-27 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
